Instead of acquiring Afrin spray over the counter which worsens the situation, patients are encouraged to seek proper medical intervention where nurses will assess them using both subjective and objective measures for seasonal allergic rhinitis (SAR). Subjective assessments by patient and nurse will comprise symptom scores and overall therapeutic response evaluation whereas objective measures will include nasal cytology, nasal airway resistance, olfactory functions, nasal biochemistry and mucociliary clearance (Brozek et al..,2017). Intranasal topical glucocorticoids are effective in reducing both subjective and objective measures of allergic rhinitis and also decreases mediator release and cytokine immunoreactivity. Mometasone being a new glucocorticoid is efficient in managing the condition when administered intranasally. Those of age twelve years and older will be prescribed 200 μg mometasone furoate nasal spray (n-80) or placebo spray (N=41) to be used once in a day for a period of two weeks.